Parmedics Inc. has described proteinase-activated PAR2 receptor antagonists reported to be useful for the treatment of asthma, cancer, osteoarthritis, migraine, chronic pain, inflammatory and vascular disorders.

Beijing Primegene Therapeutics Co. Ltd. has divulged thioether compounds acting as transient receptor potential cation channel subfamily V member 3 (TRPV3) antagonists reported to be useful for the treatment of pain, pruritus, inflammation, fever, cystitis, irritable bowel syndrome, cough and alopecia.

Beijing Danatlas Pharmaceutical Technology Co. Ltd. has identified thiadiazolyl derivatives acting as DNA polymerase θ (POLθ, POLQ) inhibitors reported to be useful for the treatment of cancer.

Flagship Pioneering Innovations VI LLC has disclosed ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of fibrosis, nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH), Parkinson’s disease and cancer.

Scientists at Cerevance Inc. and Cerevance Ltd. have described potassium channel subfamily K member 13 (KCNK13; THIK-1) blockers reported to be useful for the treatment of fibrosis, depression, diabetes, gout, psoriasis, atherosclerosis, inflammatory bowel disease and traumatic brain injury.

Xuanzhu Pharma Co. Ltd. has divulged poly (ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of atherosclerosis, cancer, epilepsy, hyperlipidemia, ischemia, osteoarthritis, pain and Alzheimer’s disease.

Sitryx Therapeutics Ltd. has identified compounds acting as pyruvate kinase M2 (PKM2) and/or PKLR activators reported to be useful for the treatment of cancer, obesity, inflammation, diabetes and hematologic disorders.

Petra Pharma Corp. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors, particularly H1047R and/or E545K mutant allosteric inhibitors. They are described as potentially useful for the treatment of cancer, PIK3CA-related overgrowth spectrum, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.

Xtalpi Inc. has disclosed ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors reported to be useful for the treatment of cancer.

Meliora Therapeutics Inc. has patented cyclin-dependent kinase 11 (CDK11) inhibitors and apoptosis inducers reported to be useful for the treatment of breast cancer and melanoma.